Organon & Co.
About Organon & Co.
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $6.2B
- Net income
- $187.0M
- Total assets
- $12.9B
- Market cap
- $3.5B
- Gross margin
- 53.3%
- Operating margin
- 6.8%
- Net margin
- 3.0%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $6.2B
- Cost of revenue
- $2.9B
- Gross profit
- $3.3B
- Operating expenses
- $2.9B
- Operating income
- $425.0M
- Income tax
- $238.0M
- Net income
- $187.0M
- EPS (basic)
- $0.72
- EPS (diluted)
- $0.72
Balance sheet
- Total assets
- $12.9B
- Current assets
- $4.4B
- Total liabilities
- $12.1B
- Current liabilities
- $2.4B
- Shareholders’ equity
- $752.0M
Cash flow
- Operating cash flow
- $700.0M
- Investing cash flow
- -$390.0M
- Financing cash flow
- -$561.0M
- Net cash flow
- -$101.0M
Statements via Polygon.io (SEC filings)
- Market cap
- $3.5B
- P/E ratio
- 18.6
- EPS (diluted)
- $0.72
- Dividend yield
- 0.6%
- Shares outstanding
- 262.2M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- May 14, 2021
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $187.0M in FY2025.
- Revenue declined 1% from FY2021 to FY2025.
- Gross margin of 53.3%, net margin 3.0%.
- Trading near its 52-week high.
- Pays a dividend yielding about 0.6% annually.
- Valued at a price-to-earnings (P/E) ratio of 18.6.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Organon & Co..
Write a review
News about Organon & Co.
News & sentiment via Polygon.io
